文献速递神经肿瘤

内镜辅助眶上锁孔入路治疗前颅底脑膜瘤的更新meta分析

The endoscope-assisted supraorbital "keyhole" approach for anterior skull base meningiomas: an updated meta-analysis.
PubMed 文献 · Acta Neurochir (Wien) · 2020-09-05

该更新meta分析比较内镜辅助眶上锁孔入路(eSKA)、显微经颅入路(mTCA)与扩大内镜经鼻入路(EEA)治疗嗅沟脑膜瘤(OGM)和鞍结节脑膜瘤(TSM)的手术结局与并发症。共纳入96项研究(TSM 2191例,OGM 1510例),mTCA全切除率最高,EEA视力改善率最高但脑脊液漏发生率也最高,eSKA不良结局未增加且疗效相当。

要点

  • eSKA全切除率(TSM 85.2%,OGM 84.9%)介于mTCA与EEA之间。
  • EEA视力改善率最高(TSM 81.9%,OGM 54.6%),但脑脊液漏发生率也最高。
  • eSKA脑脊液漏发生率低(TSM 2.1%,OGM 1.6%),所有亚组死亡率和术中动脉损伤≤1%。

核心结论

  • 在多样研究人群中,eSKA与mTCA和EEA相比未增加不良结局且疗效相当,病例选择对确立eSKA在前颅底肿瘤中的作用至关重要。

研究设计与样本

  • 更新研究级meta分析,采用随机效应模型,比较eSKA、mTCA和EEA治疗OGM和TSM的手术结局与并发症。
  • 共筛选2285篇文章,纳入96项研究,包含TSM患者2191例和OGM患者1510例。

主要发现

  • 全切除率:mTCA最高(TSM 89.6%,OGM 91.1%),eSKA次之(TSM 85.2%,OGM 84.9%),EEA最低(TSM 83.9%,OGM 82.8%)。
  • 视力改善率:EEA最高(TSM 81.9%,OGM 54.6%),eSKA次之(TSM 65.9%,OGM 52.9%),mTCA最低(TSM 63.9%,OGM 45.7%)。
  • 脑脊液漏发生率:EEA最高(TSM 9.2%,OGM 14.5%),eSKA为TSM 2.1%、OGM 1.6%,mTCA为TSM 1.6%、OGM 6.5%。
  • 所有亚组死亡率和术中动脉损伤均为1%或更低。

临床怎么用

  • eSKA可作为前颅底脑膜瘤(OGM和TSM)的手术选择之一,其疗效与mTCA和EEA相当且脑脊液漏风险较低。
  • 选择eSKA需严格评估病例,权衡全切除率、视力改善与脑脊液漏风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The gold-standard treatment for symptomatic anterior skull base meningiomas is surgical resection. The endoscope-assisted supraorbital "keyhole" approach (eSKA) is a promising technique for surgical resection of olfactory groove (OGM) and tuberculum sellae meningioma (TSM) but has yet to be compared with the microscopic transcranial (mTCA) and the expanded endoscopic endonasal approach (EEA) in the context of existing literature. METHODS: An updated study-level meta-analysis on surgical outcomes and complications of OGM and TSM operated with the eSKA, mTCA, and EEA was conducted using random-effect models. RESULTS: A total of 2285 articles were screened, yielding 96 studies (2191 TSM and 1510 OGM patients). In terms of effectiveness, gross total resection incidence was highest in mTCA (89.6% TSM, 91.1% OGM), followed by eSKA (85.2% TSM, 84.9% OGM) and EEA (83.9% TSM, 82.8% OGM). Additionally, the EEA group had the highest incidence of visual improvement (81.9% TSM, 54.6% OGM), followed by eSKA (65.9% TSM, 52.9% OGM) and mTCA (63.9% TSM, 45.7% OGM). However, in terms of safety, the EEA possessed the highest cerebrospinal fluid leak incidence (9.2% TSM, 14.5% OGM), compared with eSKA (2.1% TSM, 1.6% OGM) and mTCA (1.6% TSM, 6.5% OGM). Finally, mortality and intraoperative arterial injury were 1% or lower across all subgroups. CONCLUSIONS: In the context of diverse study populations, the eSKA appeared not to be associated with increased adverse outcomes when compared with mTCA and EEA and offered comparable effectiveness. Case-selection is paramount in establishing a role for the eSKA in anterior skull base tumours.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Khan DZ, Muskens IS, Mekary RA, et al. The endoscope-assisted supraorbital "keyhole" approach for anterior skull base meningiomas: an updated meta-analysis. Acta Neurochir (Wien). 2020. PMID: 32889640. doi:10.1007/s00701-020-04544-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。